... Investor Relations: Clayton Robertson Achillion Pharmaceuticals, Inc. Tel. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, … Media: Susanne Heinzinger Senior VP, Corporate Communications Achillion Pharmaceuticals, Inc. Tel. AstraZeneca and Alexion Combination . Full-Year 2020 Presentation. Email alerts; Results, reports and presentations; Share price and tools. Investor Relations Oxford Immunotec Global PLC is a global, high-growth diagnostics company. It has been about a month since the last earnings report for Alexion Pharmaceuticals (ALXN Quick Quote ALXN - Free Report) .Shares have lost about … The institutional investor owned 3,214 shares of the biopharmaceutical company’s stock after acquiring an additional 714 shares during the period. Details of Transaction . How medicines are making an impact in the lives of patients. Initial Public Offering (IPO) First-quarter results FY2021 I Feb 1, 2021. 215-709-3078. Thank you, operator. At Alexion, we take a comprehensive view of corporate social responsibility (CSR), which encompasses environmental, social and governance topics that impact our business and our stakeholders. The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Investors are keen to know the performance of Alexion’s long-acting C5 complement inhibitor, Ultomiris. For general inquiries, please contact our Global Headquarters at 1-475-230-2596.. To report an adverse event experience for any Alexion product, please contact us at AdverseEventReporting@alexion.com or 1-844-259-6783.. To report an issue or complaint with an Alexion product, please contact us at ProductComplaints@alexion.com.. To report a compliance or … Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. FY 2020; 9M 2020; HY 2020; Q1 2020; All; Full-Year 2020 Investor Update. Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year e On February 1st, the conference call for analysts and investors with CEO Dr. Bernd Montag and CFO Dr. Jochen Schmitz was broadcast via audio webcast. We bring energy and invention to a world in need of diagnostic truth, committed to improving patient care by providing advanced, innovative tests in the field of immunology. Data Provided by Refinitiv. Special Meeting . Alexion: Media Megan Goulart, 857-338-8634 Senior Director, Corporate Communications Investors Susan Altschuller, Ph.D., 857-338-8788 Vice President, Investor Relations Achillion: Media Susanne Heinzinger, 215-709-3032 Senior VP, Corporate Communications Investors A. Clayton Robertson, 215-709-3078 Manager, Investor Relations Investor Relations. Full-Year 2020 Presentation with appendix. Find the latest analyst research for Alexion Pharmaceuticals, Inc. Common Stock (ALXN) at Nasdaq.com. We will hold the Special Meeting on December 19, 2019, at 9:00 a.m., Eastern time, at The Union League, 140 South Broad Street, Philadelphia, Pennsylvania 19102. Investors/Media. Title 2019 Annual Report Online document PDF: Learn more through our website Web: Title 2018 Annual Report Online document PDF: Learn more through our website: Title 2017 Annual Report Online document PDF: Learn more through our website Alexion Pharmaceuticals, Inc. ALXN entered into a definitive agreement with U.K.-based pharmaceutical company, AstraZeneca plc AZN, whereby the latter will acquire the former. Alexion Reports Fourth Quarter and Full Year 2020 Results. more. Investor Relations Annual Shareholders' Meeting 2021 The Annual Shareholders' Meeting of Siemens Healthineers AG will take place on Friday, February 12, 2021, at 10:00 a.m. (CET) as a virtual Shareholders’ Meeting without the shareholders or their proxy representatives being physically present. 2019. For Media enquiries, Megan Goulart, +18573388634, and for Investor Relations, Chris Stevo, +18573389309. Questions may be directed to the Investor Relations team via e-mail at InvestorRelations@Alexion.com or the contact information below. Maintaining a strong balance sheet to fund future exploration and appraisal. Investor Relations Investors Corporate Profile. Welcome to BioMarin's Investor Relations & Media Page; Press Releases; Events & Presentations; Corporate Governance; Financial Information. Annual Report 2020; Finance Report 2020; Roche in Brief 2020 ; Historic quarterly reporting. Pending Acquisition of Achillion by Alexion. Notes. This … Good morning. Moors & Cabot Inc. lifted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 28.6% in the 4th quarter, HoldingsChannel reports. 215-709-3032. Latest annual report Highlights Annual Report 2020. Maintaining a strong balance sheet to fund future exploration and appraisal Annual Report 2019; Investment case; Financial highlights; Regulatory news. Annual Report 2020. Source: Achillion Pharmaceuticals, Inc. Investors. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Christopher Mecray - VP Investor Relations, Treasury & Strategy (215) 255-7970 christopher.mecray@axalta.com Find the latest Institutional Holdings data for Alexion Pharmaceuticals, Inc. Common Stock (ALXN) at Nasdaq.com. Alexion Makes Donations to Support Community Responses to COVID-19 Outbreak Alexion is committed to assisting communities and medical systems in their efforts to address the public health crisis caused by the COVID-19 pandemic and is taking a holistic approach to supporting our global communities across a range of areas of need. Alexion Pharmaceuticals ... Mr. Chris Stevo, head of investor relations. 2021. Contact Us. Chris Stevo-- Head of Investor Relations. Sir, you may begin. SEC Filings; Annual Reports; Quarterly Results; IR Key Ratios; Financial Statements; BioMarin UK Tax Strategy; Analyst Coverage; Stock Information; Investor FAQs; Contact Us; Email Alerts Alexion contacts . Investor Relations. 2018. Minimum 15 minutes delayed. Investor Relations Contact. In 2019, we made significant strides in formalizing our CSR commitment. 25.01.21: Alexion to Report Fourth Quarter and Full Year 2020 Results on Thursday, February 4, 2021 . 2015 - 2017. Moors & Cabot Inc.’s holdings in Alexion Pharmaceuticals were worth $502,000 at the […] 2020. Liquid biopsy is at the core of our mission to conquer cancer with data. For details on how to contact the Investor Relations Team, please click here. These efforts come to life in our 2019 CSR Report, Brighter Futures, summarized here. Presentations & Financial Publications. Alexion Reports Second Quarter 2019 Results 2Q19 total revenues of $1,203.3 million , a 15 percent increase over 2Q18 and a 23 percent volume increase 2Q19 GAAP diluted EPS of $2.04 ; non-GAAP diluted EPS of $2.64 Presentations & Financial Publications. Alexion Pharmaceuticals (ALXN) came out with quarterly earnings of $3.11 per share, beating the Zacks Consensus Estimate of $2.55 per share. Alexion and Achillion have not yet submitted their filings under the HSR Act, and currently anticipate doing so in January 2020. For Media contacts, click here.